群多普利/盐酸维拉帕米(Trandolapril/Verapamil Hydrochloride) - 药物靶点：ACE x VDCCs_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Ocadrik、Tarka、Trandolapril/verapamil

+ [1]

靶点

ACE x VDCCs

作用机制

ACE抑制剂(血管紧张素转化酶抑制剂)、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂)

治疗领域

心血管疾病

在研适应症-

非在研适应症

高血压

原研机构

AbbVie, Inc.

在研机构-

非在研机构

AbbVie, Inc.

最高研发阶段撤市

首次获批日期

美国 (1996-10-22),

高血压

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C24H34N2O5

InChIKeyVXFJYXUZANRPDJ-WTNASJBWSA-N

CAS号87679-37-6

查看全部结构式(2)

关联

5

项与群多普利/盐酸维拉帕米相关的临床试验

NCT00235001 / Completed临床4期

A Multicenter, Open, Phase IV, 24-Hour Ambulatory Blood Pressure Monitoring Study of the Efficacy and Safety of Tarka in Patients With Arterial Hypertension

This study will investigate antihypertensive activity and safety profile of Tarka in Russian hypertension patients by ambulatory blood pressure measurement (ABPM)

开始日期2004-06-01

申办/合作机构

Abbott Laboratories

NCT00234858 / Completed临床4期

A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome

The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome

开始日期2004-03-01

申办/合作机构

Abbott Laboratories

NCT00234871 / Completed临床4期

A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy

The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy

开始日期2004-01-01

申办/合作机构

Abbott Laboratories

100 项与群多普利/盐酸维拉帕米相关的临床结果

登录后查看更多信息

100 项与群多普利/盐酸维拉帕米相关的转化医学

登录后查看更多信息

100 项与群多普利/盐酸维拉帕米相关的专利（医药）

登录后查看更多信息

12

项与群多普利/盐酸维拉帕米相关的文献（医药）

2024-05-01·WMJ : official publication of the State Medical Society of Wisconsin

Use of Intravenous Lipid Emulsion Therapy and Insulin in a Case of Tarka Intoxication.

Article

作者: Arslan, İlknur ; Gün, Emrah ; Çiçek, Mahmut ; Kendirli, Tanıl ; Kafalı, Mustafa ; Demir, Hüsnü

INTRODUCTIONTarka (trandolapril/verapamil hydrohloride extended-release) is a fixed-dose combination antihypertensive drug formed from verapamil hydrochloride and trandolapril. Toxicologic manifestations of Tarka overdose are altered mental status, bradycardia, hypotension, atrioventricular block (first-degree), hyperglycemia, metabolic acidosis, and shock.CASE PRESENTATIONWe report a case of Tarka toxicity in a 2-year-old girl who presented with altered mental status, cardiogenic shock, hypotension, bradycardia, severe metabolic acidosis, hyperglycemia, and first-degree atrioventricular block. We started fluid resuscitation, epinephrine, norepinephrine, and insulin. Because of the patient's hyperlactatemia and hypotension despite standard therapies, we initiated intravenous lipid emulsion (ILE) therapy, after which her condition improved promptly.DISCUSSIONTarka overdose may be life-threatening as it can cause cardiogenic shock. In our patient, the regression of lactate elevation in a short time with ILE therapy and the improvement of her general condition highlight the importance of ILE.CONCLUSIONSILE is an alternative treatment method for acute lipophilic drug intoxications, such as Tarka.

2016-01-01·Yonsei Medical Journal4区 · 医学

Target Blood Pressure in Patients with Diabetes: Asian Perspective

4区 · 医学

ReviewOA

作者: Wang, Ji-Guang ; Hoshide, Satoshi ; Cheng, Hao-min ; Park, Chang-Gyu ; Park, Sungha ; Chen, Chen-Huan ; Kario, Kazuomi ; Huang, Qi-Fang

Recently, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) blood pressure (BP) trial enrolled 4733 participants with type 2 diabetes and randomized them to a target systolic blood pressure (SBP) of less than 120 mm Hg or 140 mm Hg. Despite the significant difference in the achieved SBP, there was no significant difference in the incidence of primary outcomes. Based on this evidence, the target SBP for diabetics has been revised in the majority of major guidelines. However, there is a steeper association between SBP and stroke in Asians than other ethnicities, with stroke being the leading cause of cardiovascular mortality. This suggests that target BP in the Asian region should be tailored towards prevention of stroke. In the ACCORD study, the intensive BP treatment was associated with significant reductions in both total stroke and non-fatal stroke. The results from the ACCORD study are supported by a subgroup analysis from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study, which showed that, in diabetic patients, the risk of stroke continues to decrease to a SBP value of 115 mm Hg with no evidence of J curve. As diabetes is highly associated with underlying coronary artery disease, there is a justified concern for adverse effects resulting from too much lowering of BP. In a post hoc analysis of 6400 diabetic subjects enrolled in the International Verapamil SR-Trandolapril (INVEST) study, subjects with SBP of less than 110 mm Hg were associated with a significant increase in all-cause mortality. In the ONTARGET study, at any levels of achieved SBP, diastolic blood pressure (DBP) below 67 mm Hg was associated with increased risk for cardiovascular outcomes. As such, a prudent approach would be to target a SBP of 130-140 mm Hg and DBP of above 60 mm Hg in diabetics with coronary artery disease. In conclusion, hypertension, in association with diabetes, has been found to be significantly correlated with an elevated risk for cardiovascular events. As the association between stroke and BP is stronger in Asians, compared to other ethnicities, consideration should be given for a target BP of 130/80 mm Hg in Asians.

2014-03-01·Journal of Hypertension2区 · 医学

Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension

2区 · 医学

Article

作者: Gong, Yan ; Smith, Steven M. ; Messerli, Franz H. ; Ahmed, Ali ; Pepine, Carl J. ; Cooper-DeHoff, Rhonda M. ; Bakris, George L. ; Bavry, Anthony A. ; Handberg, Eileen

OBJECTIVEResistant hypertension (res-HTN) is a challenging problem, but little is known of res-HTN in patients with coronary artery disease (CAD). In this post-hoc INternational VErapamil SR-Trandolapril STudy (INVEST) analysis, we assessed prevalence, predictors, and impact on outcomes of res-HTN in CAD patients with hypertension.METHODSParticipants (n=17190) were divided into three groups according to achieved blood pressure (BP): controlled (BP <140/90 mmHg on three or fewer drugs); uncontrolled (BP ≥ 40/90 mmHg on two or fewer drugs); or resistant (BP ≥ 40/90 mmHg on three drugs or any patient on at least four drugs).RESULTSThe prevalence of res-HTN was 38%: significant predictors of res-HTN included heart failure [odds ratio (OR) 1.73], diabetes (OR 1.63), Black race (OR 1.50), and US residence (OR 1.50). Compared with controlled HTN, res-HTN had multivariate-adjusted association with higher risk of adverse outcomes {first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke [hazard ratio 1.27, 95% confidence interval (CI) 1.13-1.43], and individual outcomes of all-cause death (hazard ratio 1.29, 95% CI 1.13-1.48), cardiovascular mortality (hazard ratio 1.47, 95% CI 1.21-1.78), and nonfatal stroke (hazard ratio 1.61, 95% CI 1.17-2.22), but not nonfatal myocardial infarction (hazard ratio 0.98, 95% CI 0.72-1.34)}. Adverse outcomes, except nonfatal stroke, did not differ in patients with res-HTN compared to uncontrolled HTN.CONCLUSIONSRes-HTN is common in patients with CAD and hypertension, associated with poor prognosis, and linked with a number of conditions. Emphasis should be placed on recognizing those at risk for res-HTN and future studies should examine whether more aggressive treatment of res-HTN improves outcomes.

100 项与群多普利/盐酸维拉帕米相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	群多普利/盐酸维拉帕米	C09BB10	-

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00235014 (BENEDICT-B, Pubmed \| J Hypertens)	临床4期	糖尿病肾病 \| 高血压	281	Verapamil/trandolapril 180 mg/2 mg daily	築廠壓顧壓製積齋網構(窪積願夢憲餘廠願夢獵): hazard ratio = 0.93 (95% CI, 0.5 ~ 1.72), P-Value = 0.816 更多	不佳	2011-02-01
				Trandolapril 2 mg daily